Acumen Pharmaceuticals (ABOS) News Today $2.40 -0.21 (-8.05%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest UpdateAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) saw a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 1,450,000 shares, a growth of 14.2% from the October 15th total of 1,270,000 shares. Approximately 3.2% of the company's stock are short sold. Based on an average daily volume of 184,900 shares, the short-interest ratio is currently 7.8 days.November 16 at 6:51 AM | marketbeat.comAcumen Pharmaceuticals Advances Alzheimer’s TherapeuticNovember 14 at 4:14 AM | markets.businessinsider.comBank of America Securities Keeps Their Buy Rating on Acumen Pharmaceuticals (ABOS)November 14 at 4:14 AM | markets.businessinsider.comAcumen Pharmaceuticals (NASDAQ:ABOS) Receives "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $15.00 target price on shares of Acumen Pharmaceuticals in a research note on Wednesday.November 13, 2024 | marketbeat.comQ3 2024 Acumen Pharmaceuticals Inc Earnings CallNovember 13, 2024 | uk.finance.yahoo.comAcumen Pharmaceuticals Inc (ABOS) Q3 2024 Earnings Call Highlights: Strong Cash Position and ...November 13, 2024 | finance.yahoo.comAcumen Pharmaceuticals' Shares Drop on Wider 3Q LossNovember 13, 2024 | marketwatch.comAcumen Pharma Reports Q3 2024, Highlights Alzheimer’s FocusNovember 13, 2024 | markets.businessinsider.comAcumen Pharmaceuticals, Inc. (ABOS) Q3 2024 Earnings Call TranscriptNovember 12, 2024 | seekingalpha.comAcumen Pharmaceuticals Earnings PreviewNovember 12, 2024 | benzinga.comAcumen Pharmaceuticals to Participate in the Stifel Healthcare ConferenceNovember 11, 2024 | globenewswire.comAcumen Pharmaceuticals (ABOS) Set to Announce Earnings on TuesdayNovember 10, 2024 | americanbankingnews.comAcumen appoints Schacterle as Chief Regulatory Officer, Head of QualityNovember 6, 2024 | markets.businessinsider.comAcumen Pharmaceuticals to Participate in the UBS Global Healthcare ConferenceNovember 6, 2024 | globenewswire.comAcumen Pharmaceuticals Appoints Dr. Amy Schacterle as Chief Regulatory Officer & Head of QualityNovember 6, 2024 | markets.businessinsider.comAcumen Pharmaceuticals (ABOS) Scheduled to Post Earnings on TuesdayAcumen Pharmaceuticals (NASDAQ:ABOS) will be releasing earnings before the market opens on Tuesday, November 12, Zacks reports.November 6, 2024 | marketbeat.comAcumen presents data on pTau217 assay to screen for Phase 2 ALTITUDE-AD trialNovember 1, 2024 | markets.businessinsider.comAcumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease ConferenceOctober 31, 2024 | globenewswire.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Down 18.6% in OctoberAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) saw a significant decline in short interest in October. As of October 15th, there was short interest totalling 1,270,000 shares, a decline of 18.6% from the September 30th total of 1,560,000 shares. Based on an average trading volume of 203,200 shares, the short-interest ratio is currently 6.3 days. Approximately 2.8% of the shares of the stock are short sold.October 28, 2024 | marketbeat.comAcumen to deliver late-breaking presentation on ACU193 at CTAD conferenceOctober 24, 2024 | markets.businessinsider.comAcumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) ConferenceOctober 24, 2024 | markets.businessinsider.comAcumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) ConferenceOctober 23, 2024 | globenewswire.comAcumen Pharmaceuticals (NASDAQ:ABOS) Stock, Insider Trading ActivityOctober 21, 2024 | benzinga.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Sees Large Decline in Short InterestAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) was the target of a large drop in short interest in the month of September. As of September 30th, there was short interest totalling 1,560,000 shares, a drop of 7.7% from the September 15th total of 1,690,000 shares. Approximately 3.5% of the company's shares are short sold. Based on an average trading volume of 254,100 shares, the short-interest ratio is presently 6.1 days.October 16, 2024 | marketbeat.comMillennium Management LLC Cuts Stock Position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)Millennium Management LLC lessened its position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Free Report) by 25.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,954,085 shares of the company's stock after selling 675,456October 13, 2024 | marketbeat.comRenaissance Technologies LLC Invests $818,000 in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)Renaissance Technologies LLC purchased a new stake in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 338,100 shares of the company's stock, valued at approximately $818,000. RenOctober 8, 2024 | marketbeat.comBuy Rating Affirmed for Acumen Pharmaceuticals Amid Promising Sabirnetug Alzheimer’s Treatment DataOctober 4, 2024 | markets.businessinsider.comStrong Buy Rating for Acumen Pharmaceuticals Amid Promising Trial Results for Lead Candidate ACU193October 4, 2024 | markets.businessinsider.comAcumen Pharmaceuticals (NASDAQ:ABOS) Given "Buy" Rating at HC WainwrightHC Wainwright restated a "buy" rating and set a $15.00 price objective on shares of Acumen Pharmaceuticals in a research report on Thursday.October 3, 2024 | marketbeat.comAcumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual ConferenceSeptember 30, 2024 | globenewswire.comAcumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s DiseaseSeptember 26, 2024 | finance.yahoo.comAcumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024September 25, 2024 | globenewswire.comAcumen Pharmaceuticals (NASDAQ:ABOS) Trading 9.9% Higher Acumen Pharmaceuticals (NASDAQ:ABOS) Stock Price Up 9.9%September 10, 2024 | marketbeat.comAcumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor ConferenceSeptember 3, 2024 | globenewswire.comAnalysts Issue Forecasts for Acumen Pharmaceuticals, Inc.'s FY2024 Earnings (NASDAQ:ABOS)Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Free Report) - HC Wainwright lifted their FY2024 EPS estimates for shares of Acumen Pharmaceuticals in a report issued on Wednesday, August 14th. HC Wainwright analyst A. Fein now expects that the company will post earnings of ($1.01) per share for theAugust 16, 2024 | marketbeat.comAcumen Pharmaceuticals (NASDAQ:ABOS) PT Lowered to $6.00UBS Group dropped their target price on shares of Acumen Pharmaceuticals from $14.00 to $6.00 and set a "buy" rating for the company in a report on Thursday.August 15, 2024 | marketbeat.comBuy Rating for Acumen Pharmaceuticals Backed by Promising Alzheimer’s Treatment Advances and Strong FinancialsAugust 14, 2024 | markets.businessinsider.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q2 2024 Earnings Call TranscriptAugust 14, 2024 | msn.comQ2 2024 Acumen Pharmaceuticals Inc Earnings CallAugust 14, 2024 | finance.yahoo.comAcumen Pharmaceuticals, Inc. (ABOS) Q2 2024 Earnings Call TranscriptAugust 13, 2024 | seekingalpha.comAcumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business HighlightsAugust 13, 2024 | markets.businessinsider.comAcumen Pharmaceuticals (ABOS) Set to Announce Quarterly Earnings on TuesdayAcumen Pharmaceuticals (NASDAQ:ABOS) will be releasing earnings before the market opens on Tuesday, August 13, Zacks reports.August 7, 2024 | marketbeat.comAcumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024August 6, 2024 | globenewswire.comPrice T Rowe Associates Inc. MD Takes Position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)Price T Rowe Associates Inc. MD purchased a new position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 1,098,276 shares of the company's stock, valuedAugust 5, 2024 | marketbeat.comAcumen Pharmaceuticals: Healthy Cash Runway And Market Potential In Alzheimer'sJuly 30, 2024 | seekingalpha.comAcumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer’s DiseaseJuly 29, 2024 | markets.businessinsider.comAcumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer's DiseaseJuly 29, 2024 | globenewswire.comAcumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer's Association International Conference (AAIC®) 2024July 28, 2024 | globenewswire.comCitigroup Initiates Coverage of Acumen Pharmaceuticals (ABOS) with Buy RecommendationJuly 26, 2024 | msn.comShort Interest in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Rises By 39.4%Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) was the target of a large growth in short interest in the month of June. As of June 30th, there was short interest totalling 990,400 shares, a growth of 39.4% from the June 15th total of 710,600 shares. Based on an average daily trading volume, of 364,600 shares, the days-to-cover ratio is presently 2.7 days. Approximately 2.2% of the company's stock are short sold.July 13, 2024 | marketbeat.com Get Acumen Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ABOS and its competitors with MarketBeat's FREE daily newsletter. Email Address The only candlestick pattern worth a darn (Ad)It’s widely known that 80% of daily market action is driven by Wall Street algorithms… Now, most people think of the algorithms are “bad” When in reality, they are neither good nor bad… They are simply programmed to buy and sell certain stocks over and over again… But here is the thing… They are predictable… They typically buy the same stocks at the same levels over and over again… Follow this link here and enter your email address to sign up… ABOS Media Mentions By Week ABOS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ABOS News Sentiment▼0.200.55▲Average Medical News Sentiment ABOS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ABOS Articles This Week▼152▲ABOS Articles Average Week Get Acumen Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ABOS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies OVID News Today QNCX News Today ACIU News Today HUMA News Today SANA News Today PHVS News Today ATXS News Today OCS News Today KRRO News Today PROK News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ABOS) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acumen Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acumen Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
